CRSP-ONC-005 (Solid Tumors)

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called CTX131 (the study drug) is a safe and effective treatment for different forms of cancer with solid tumors. The study drug is made from white blood cells or T cells from healthy donors.

What is the Condition Being Studied?

Clear Cell Renal Carcinoma (ccRCC), Cervical Carcinoma (CC), Esophageal Carcinoma (EC), Pancreatic Adenocarcinoma (PAC), Malignant Pleural Mesothelioma (MPM)

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with clear cell renal carcinoma (ccRCC), cervical carcinoma (CC), esophageal carcinoma (EC), pancreatic adenocarcinoma (PAC), or malignant pleural mesothelioma (MPM)
  • Have received at least one round of previous treatment
  • Have never received treatment with anti-CD70 targeting agents

    • For more information about who can join this study, please contact the study team at 919-681-6468.

    Age Group
    Adults

    What is Involved?

    If you choose to join this study, you will:

    • Receive lympho-depleting chemotherapy
    • Take the study drug
    • Provide tumor tissue
    • Have physical exams and blood draws
    • Have imaging scans (CT and/or MRI)
    • Have heart tests (ECG)

    Study Details

    Full Title
    A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors
    Principal Investigator
    Headshot of Christopher Hoimes
    Instructor in the Department of Medicine
    Protocol Number
    IRB: PRO00112460
    NCT: NCT05795595
    Phase
    Phase I/II
    ClinicalTrials.gov
    Enrollment Status
    OPEN TO ACCRUAL
    Participate